Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions

Overview

Journal PLoS Negl Trop Dis

Specialties Infectious Diseases
Tropical Medicine

Date 2014 Aug 29

PMID 25166493

Citations 27

Authors

James Whitehorn

Sophie Yacoub

Katherine L Anders

Louis R Macareo

M Cristina Cassetti

Vinh Chau Nguyen Van

Pei-Yong Shi

Bridget Wills

Cameron P Simmons

Affiliations

Soon will be listed here.

Abstract

Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.

Citing Articles

Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial.

Huyen T, Trieu H, Vuong N, Minh Nguyet N, Tam D, McBride A Wellcome Open Res. 2025; 9:689.

PMID: 39931105 PMC: 11809184. DOI: 10.12688/wellcomeopenres.21017.1.

Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.

Xu J, Zhang W, Fu J, Fang X, Gao C, Li C Mil Med Res. 2024; 11(1):78.

PMID: 39676169 PMC: 11648306. DOI: 10.1186/s40779-024-00581-0.

Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.

Ackaert O, Vanhoutte F, Verpoorten N, Buelens A, Lachau-Durand S, Lammens L Clin Infect Dis. 2023; 77(6):857-865.

PMID: 37161721 PMC: 10506772. DOI: 10.1093/cid/ciad284.

Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.

Goethals O, Kaptein S, Kesteleyn B, Bonfanti J, Van Wesenbeeck L, Bardiot D Nature. 2023; 615(7953):678-686.

PMID: 36922586 PMC: 10033419. DOI: 10.1038/s41586-023-05790-6.

Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions.

Shorobi F, Nisa F, Saha S, Hasan Chowdhury M, Srisuphanunt M, Hossain K Molecules. 2023; 28(3).

PMID: 36770606 PMC: 9920550. DOI: 10.3390/molecules28030938.

References

Castro J, Vado-Solis I, Perez-Osorio C, Fredeking T . Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol. 2011; 2011:370872. PMC: 3065216. DOI: 10.1155/2011/370872. View

Vincent J, Kellum J, Shaw A, Mythen M . Should hydroxyethyl starch solutions be totally banned?. Crit Care. 2013; 17(5):193. PMC: 3871763. DOI: 10.1186/cc13027. View

Thomas S . Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother. 2013; 9(7):1587-90. DOI: 10.4161/hv.24188. View

Yeo T, Lampah D, Gitawati R, Tjitra E, Kenangalem E, McNeil Y . Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med. 2007; 204(11):2693-704. PMC: 2118490. DOI: 10.1084/jem.20070819. View

Assir M, Kamran U, Ahmad H, Bashir S, Mansoor H, Bin Anees S . Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. Transfus Med Hemother. 2013; 40(5):362-8. PMC: 3822277. DOI: 10.1159/000354837. View

Wills B, Nguyen M, Ha T, Dong T, Tran T, Le T . Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005; 353(9):877-89. DOI: 10.1056/NEJMoa044057. View

Halstead S, Shotwell H, Casals J . Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis. 1973; 128(1):7-14. DOI: 10.1093/infdis/128.1.7. View

Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S . Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380(9853):1559-67. DOI: 10.1016/S0140-6736(12)61428-7. View

Buchele G, Silva E, Ospina-Tascon G, Vincent J, De Backer D . Effects of hydrocortisone on microcirculatory alterations in patients with septic shock. Crit Care Med. 2009; 37(4):1341-7. DOI: 10.1097/ccm.0b013e3181986647. View

10.

Lum L, Abdel-Latif M, Goh A, Chan P, Lam S . Preventive transfusion in Dengue shock syndrome-is it necessary?. J Pediatr. 2003; 143(5):682-4. DOI: 10.1067/s0022-3476(03)00503-1. View

11.

Whitehorn J, Vinh Chau N, Truong N, Tai L, Van Hao N, Hien T . Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials. 2012; 13:203. PMC: 3495012. DOI: 10.1186/1745-6215-13-203. View

12.

Ngo N, Cao X, Kneen R, Wills B, Nguyen V, Nguyen T . Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis. 2001; 32(2):204-13. DOI: 10.1086/318479. View

13.

Dung N, Day N, Tam D, Loan H, Chau H, Minh L . Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis. 1999; 29(4):787-94. DOI: 10.1086/520435. View

14.

Simmons C, Wolbers M, Nguyen M, Whitehorn J, Shi P, Young P . Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis. 2012; 6(9):e1752. PMC: 3459884. DOI: 10.1371/journal.pntd.0001752. View

15.

Omatsu T, Moi M, Hirayama T, Takasaki T, Nakamura S, Tajima S . Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol. 2011; 92(Pt 10):2272-2280. DOI: 10.1099/vir.0.031229-0. View

16.

Tam D, Ngoc T, Tien N, Kieu N, Thuy T, Thanh L . Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis. 2012; 55(9):1216-24. PMC: 3466094. DOI: 10.1093/cid/cis655. View

17.

Yeo T, Lampah D, Gitawati R, Tjitra E, Kenangalem E, McNeil Y . Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis. 2008; 198(4):602-8. PMC: 2709993. DOI: 10.1086/590209. View

18.

Huy N, Thao N, Ha T, Lan N, Nga P, Thuy T . Development of clinical decision rules to predict recurrent shock in dengue. Crit Care. 2013; 17(6):R280. PMC: 4057383. DOI: 10.1186/cc13135. View

19.

Dimaano E, Saito M, Honda S, Miranda E, Alonzo M, Valerio M . Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg. 2008; 77(6):1135-8. View

20.

Falagas M, Makris G, Matthaiou D, Rafailidis P . Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother. 2008; 61(4):774-85. DOI: 10.1093/jac/dkn019. View